机构地区:[1]中国中医科学院西苑医院老年病科,北京100091
出 处:《国际中医中药杂志》2014年第1期36-39,共4页International Journal of Traditional Chinese Medicine
基 金:国家自然基金资助项目(项目编号:81173617)
摘 要:目的 观察降糖化瘀中药组分对糖尿病肾病模型大鼠氧化应激的影响并探讨相关机制.方法 SD大鼠72只应用链脲佐菌素(STZ)复制糖尿病大鼠模型,造模成功4周后将50只符合糖尿病肾病模型大鼠按照随机数字表法随机分为5组,分别为降糖化瘀中药组分高、中、低剂量组(给药剂量0.45 g/kg2d-1、0.15 g/kg2d-1、0.05 g/kg2d-1)、二甲双胍组(0.05 g/kg/d)、模型对照组,每组10只,另取10只健康大鼠作为空白对照组.连续给药4周后观察血糖、尿素氮(BUN)、SCr(血浆肌酐)、24 h尿蛋白定量(24Upro)、丙二醛(MDA)、超氧化物歧化酶(SOD)、一氧化氮(NO)、一氧化氮合酶(NOS)含量变化及肾脏病理改变.结果 模型对照组大鼠血糖、BUN、SCr、24Upro、MDA、NO、NOS分别为(13.46±7.39)mmol/L、(15.64±3.27)mmol/L、(79.52±13.22)μmol/L、(66.38±22.58)mg/d、(12.39±3.18)nmol/ml、(8.45±2.23)μmol/L、(31.64±2.36)U/ml水平明显高于空白对照组(4.61±0.63)mmol/L、(6.79±2.31)mmol/L、(55.21±9.77)μmol/L、(6.91±2.16)mg/d、(6.02±1.38)nmol/ml、(4.70±0.75)μmol/L、(27.75±1.94)U/ml),SOD(165.7±26.7)U/ml)水平低于空白对照组(280.0±18.9)U/ml.中药组分高剂量组血糖、BUN、SCr、24Upro、MDA、NO、NOS(6.68±2.39)mmol/L、(10.47±2.09)mmol/L、(57.24±11.53) μmol/L、(33.51±12.11)mg/d、(7.99±2.41)nmol/ml、(6.15±1.55) μmol/L、(27.59±1.66)U/ml水平有明显下降趋势(P<0.05,P<0.01);而SOD(205.0±19.4)U/ml有明显升高趋势(P<0.01).结论 降糖化瘀中药组分可通过降低氧化应激产物水平,增加抗氧化应激产物含量,调整机体的氧化及抗氧化平衡,起到保护肾脏的作用.Objective To observe the effects of hypoglycemic Chinese medicine components on oxidative stress in diabetic nephropathy rats and discuss the mechanism. Methods 50 diabetic nephropathy model rats treated with streptozotocin (STZ) were randomly divided into 5 groups, respectively, hypoglycemic Chinese medicine components high, middle, amd low dose group(0.45, 0.15, 0.05 g/kg/d), a metformin group (0.05 g/kg/d), and a model control group, with 10 rats in each group; another 10 healthy rats were used as blank control group. After continuous administration of medicines for 4 weeks, blood urea nitrogen (BUN), SCr(serum creatinine), 24 hour urinary protein quantitative (24Upro), malondialdehyde (MDA), superoxide dismutase (SOD), nitric oxide (NO), nitric oxide synthase (NOS) and content changes of kidney pathology were observed. Results FBS, BUN, SCr, 24Upro, MDA, NO, NOS of the rats in the model control group were (13.46 ± 7.39) mmol/L, (15.64±3.27)mmol/L, (79.52±13.22) μmol/L, (66.38±22.58)mg/d, (12.39± 3.18) nmol/ml, (8.45 ± 2.23) U/ml, and (31.64 ± 2.36) μmol/L, these values were significantly higher than those 26.7) U/ml in the model control group was lower than the blank control group (280± 18.9) U/ml. FBS, BUN, in the blank control group (4.1± 0.63) mmol/L, (6.79±2.31)mmol/L, (55.21±9.77) μmol/L, (6.91± 2.16) mg/d,(6.02± 1.38)mmol/ml, (4.70±0.75)junol/L, and (27.75± 1.94)U/ml. While the SOD level of (165.7 SCr, 24Upro, MDA, NO, and NOS in the hypoglycemic Chinese medicine components high dose group were (6.68 ± 2.39)mmol/L, (10.47 ±± 2.09) mmol/L, (57.244- ll.53)lamol/L, (33.51± 12.11)mg/d, (7.99 ± 2.41) nmol/ml, (6.15± 1.55)/lmol/L, and (27.59-t-1.66)U/ml, showing a significant downward trend compared with model control group (P〈0.05); but SOD(205± 19.4)U/ml level showed a upward tread than the model control group(P〈0.01). Conclusion Hypogly
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...